[在接受Abemaciclib-A多中心回顾性研究的患者中降低剂量的危险因素]
Akihito Kodama1, Shinji Horibata, Hironobu Kuramoto
1Dept. of Pharmacy, Suita Municipal Hospital.
Gan to kagaku ryoho. Cancer & chemotherapy
|November 18, 2025
概括
高龄和较低的基线中性粒细胞计数增加了由于腹和中性粒细胞衰竭等副作用而导致乳腺癌患者减少abemaciclib剂量的风险.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 阿贝马西克利布是一种用于HR+/HER2-乳腺癌的CDK4/6抑制剂.
- 腹和中性质减肥等不良事件可能需要降低剂量.
- 降低剂量可能会影响治疗疗效和患者预后.
研究的目的:
- 为了确定因不良事件而减少abemaciclib剂量的风险因素.
- 分析与降低abemaciclib治疗强度相关的患者特征.
主要方法:
- 对73名接受abemaciclib治疗的乳腺癌患者的回顾性研究 (2018年12月-2022年12月).
- 后勤回归分析,以确定剂量减少的风险因素.
- 标准剂量和剂量减少组之间的比较.
主要成果:
- 47.9%的患者需要降低剂量,最常见的是腹和中性衰竭.
- 多变量分析确定年龄≥65岁 (OR:4.84) 和基线中性粒细胞计数<3,660/μL (OR:5.24) 作为显著的危险因素.
- 65岁以上的患者和基线中性粒细胞较低的患者显著更有可能减少他们的abemaciclib剂量.
结论:
- 65岁或以上的年龄和基线中性粒细胞计数≤3,660/μL与降低abemaciclib剂量的风险增加有关.
- 需要进一步的研究来评估剂量降低对治疗结果和持续时间的影响.
相关概念视频
Bioavailability: Influencing Factors
320
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
320
Factors Affecting Protein-Drug Binding: Patient-Related Factors
291
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
291
Therapeutic Drug Monitoring: Affecting Factors
183
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
183
Drug Dosing: Geriatric Patients
214
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
214
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
Bioavailability Study Design: Single Versus Multiple Dose Studies
189
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
189

